Allogene Therapeutics, Inc. (ALLO) Free cash flow 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$149.6MFY2025 · since FY2018: -$47.9M → -$149.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$149.6M | +25.6% |
| FY2024 | -$201.0M | +16.0% |
| FY2023 | -$239.2M | -6.0% |
| FY2022 | -$225.7M | -9.4% |
| FY2021 | -$206.3M | -13.9% |
| FY2020 | -$181.1M | +3.8% |
| FY2019 | -$188.1M | -292.9% |
| FY2018 | -$47.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net incomeALLO Net marginALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Operating cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →